Deubiquitinating Enzyme CYLD

• 

  Subject Areas on Research

  • CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis. 
  • CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways. 
  • CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels. 
  • Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. 
  • High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid.